NCT04515927View on ClinicalTrials.gov

To Evaluate the Efficacy and Safety of JS002 in HoFH Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

August 17, 2020

Primary Completion Date

May 6, 2022

Study Completion Date

July 29, 2022

Conditions
Hyperlipemia
Interventions
DRUG

JS002

Biological: JS002 Administered by subcutaneous injection

Trial Locations (1)

Unknown

Beijing Anzhen Hospital Capital Medical University, Beijing

All Listed Sponsors
lead

Shanghai Junshi Bioscience Co., Ltd.

OTHER

NCT04515927 - To Evaluate the Efficacy and Safety of JS002 in HoFH Patients | Biotech Hunter | Biotech Hunter